Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets—such as enzymes or receptors—by inhibiting or ...

Radiopharmaceuticals represent a promising new frontier in cancer therapy. In the United States, cancer is the second leading cause of death. There is an urgent need to develop new therapies to meet ...

The second Society of Nuclear Medicine and Molecular Imaging (SNMMI) AI Summit, organized by the SNMMI AI Task Force, took ...

Figure][1] Jason S. Lewis, PhD Professor Jason S. Lewis holds the Emily Tow Chair at Memorial Sloan Kettering (MSK) in New York. He serves as deputy director of the Sloan Kettering Institute, ...

Incidental findings from PET are common, induce unnecessary patient anxiety, and incur substantial costs to the health care system, with further diagnostic clarification potentially delaying important ...

Journal of Nuclear Medicine February 2026, jnumed.123.266357; DOI: https://doi.org/10.2967/jnumed.123.266357 ...

Journal of Nuclear Medicine February 2026, jnumed.125.271098; DOI: https://doi.org/10.2967/jnumed.125.271098 ...

Recently, a collaborative effort among research centers in the United States and Europe resulted in the development of ...

Journal of Nuclear Medicine February 2026, jnumed.125.271410; DOI: https://doi.org/10.2967/jnumed.125.271410 ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

Journal of Nuclear Medicine December 2025, jnumed.125.271103; DOI: https://doi.org/10.2967/jnumed.125.271103 ...

Journal of Nuclear Medicine December 2025, jnumed.125.271248; DOI: https://doi.org/10.2967/jnumed.125.271248 ...